Albuterol (as sulfate) 0.63mg/3mL (0.021%), 1.25mg/3mL (0.042%); preservative-free. Avoid excessive use. Sensitivity to sympathomimetics. Consider higher dose albuterol product in acute attack.

Albuterol (as sulfate) 0.5%. By nebulizer: 2.5mg (0.5mL of 0.5% diluted to 3mL with sterile normal saline, or 3mL of 0.083%) 3–4 times daily. Avoid excessive use. Sensitivity to sympathomimetics.

Leak Rate. It is common for MDIs to lose propellant during storage. The propellant-leak rate of the test MDIs was compared with that of the controls (Figure 3). The leak rates for the Proventil ...

Seven Proventil HFA (albuterol sulfate 6.7 g hydrofluoroalkane inhalation aerosol ... was rinsed with 50 mL of mobile phase, and the solution was filtered K before assay. The impactor plate ...

This leaflet answers some common questions about Atrovent Inhalation Solution. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist.

The company has received approximately 3,000 complaints about its albuterol sulfate inhalation aerosol product since the start of commercial manufacturing in April 2020, according to the FDA.

The inhalers affected by this price cap include: - Combivent Respimat (ipratropium bromide and albuterol) inhalation spray ..

In February 2010, aztreonam for inhalation solution (Cayston; Gilead) — an inhalable formulation of the monobactam antibiotic aztreonam and lysine — was approved by the US FDA to improve ...

This story appears in the December 2011 issue of National Geographic magazine. At the time of Jack the Ripper, a hard time for London, there lived in that city a mild-mannered stenographer named ...

CRN‘s Solution Provider 500 ranks the top integrators, service providers and IT consultants in North America by services revenue. CRN breaks out which solution providers in each U.S. state and ...

Christensen, Clayton M., and Michael E. Raynor. The Innovator's Solution: Creating and Sustaining Successful Growth. Boston: Harvard Business School Press, 2003.

Our lead program, molgramostim inhalation solution, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar ...